Abstract
Drug discrimination was used to examine the effects of benzodiazepine (BZ)1 receptor-selective ligands in rhesus monkeys. In diazepam-treated (5.6 mg/kg, p.o.) monkeys discriminating the nonselective BZ antagonist flumazenil (0.32 mg/kg, s.c.), the BZ1-selective antagonist β-carboline-3-carboxylate-t-butyl ester (β-CCt) substituted for flumazenil. The onset of action of β-CCt was delayed with a dose of 5.6 mg/kg β-CCt substituting for flumazenil 2 h after injection. In monkeys discriminating the nonselective BZ agonist midazolam (0.56 mg/kg, s.c.), the BZ1-selective agonists zaleplon (ED50 = 0.78 mg/kg) and zolpidem (ED50 = 1.73 mg/kg) substituted for midazolam. The discriminative stimulus effects of midazolam, zaleplon, and zolpidem were antagonized by β-CCt (1.0–5.6 mg/kg, s.c.), and the effects of zaleplon and zolpidem were also antagonized by flumazenil (0.01–0.32 mg/kg, s.c.). Schild analyses supported the notion of a simple, competitive interaction between β-CCt and midazolam (slope = −1.08; apparent pA2 = 5.41) or zaleplon (slope = −1.57; apparent pA2 = 5.49) and not between β-CCt and zolpidem. Schild analyses also were consistent with a simple, competitive interaction between flumazenil and zaleplon (slope = −1.03; apparent pA2 = 7.45) or zolpidem (slope = −1.11; apparent pA2 = 7.63). These results suggest that the same BZ receptor subtype(s) mediate(s) the effects of midazolam, zolpidem, and zaleplon under these conditions and that selective binding of BZ ligands does not necessarily confer selective effects in vivo.
Footnotes
-
This research was supported by National Institute on Drug Abuse Grant DA09157. C.P.F. is the recipient of a Research Scientist Development Award (DA00211).
- Abbreviations:
- GABAA
- γ-aminobutyic acidA
- BZ
- benzodiazepine
- β-CCt
- β-carboline-3-carboxylate-t-butyl ester
- CL
- confidence limit
- FR
- fixed ratio
- Received August 7, 2001.
- Accepted October 19, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|